Five takeaways on progress altering the Parkinson’s therapeutic landscape, from day two of The Michael J. Fox Foundation’s ...

Each year, The Michael J. Fox Foundation (MJFF) hosts the Parkinson’s Disease Therapeutics Conference (PDTC), the world’s only scientific meeting devoted exclusively to Parkinson’s drug development.

We’re thrilled to be back for another year at Carson Beach! Whether you walk, run, volunteer, or cheer from the sidelines, your participation helps fuel progress and brings us closer to a cure.

Managing Parkinson’s medications can be a complex task no matter where you or your loved one are in your journey with PD. When is it best to start or adjust medication? How much should you take? How ...

There is a genetic component to Parkinson’s, with researchers estimating that about 30 percent of Parkinson’s risk is explained by genetics. Less than 10 percent of this risk has been explained by ...

Dr. Shill received her medical degree from the University of Arizona, College of Medicine. She completed her internship at St. Joseph’s Hospital and Medical Center in internal medicine. Dr. Shill ...

Donna Krenicki believes in momentum. Whether she’s hiking, golfing or spending the day with her young grandchildren (five under the age of 5), movement has always been central to her life. It’s how ...

The Michael J. Fox Foundation for Parkinson’s Research invites you to our free educational event for people with Parkinson’s and their loved ones. Join us in Washington, D.C. on October 24, 2026 at ...

A new study shows the annual incidence of Parkinson’s disease (PD) among older adults in the United States is nearly 50 percent higher than the rate currently estimated. Incidence refers to new cases ...

A new report released on March 26, 2026, by The Michael J. Fox Foundation (MJFF) shows that the annual economic impact of Parkinson’s disease and atypical parkinsonisms in the United States reached ...

The U.S. Food and Drug Administration (FDA) has approved tavapadon, a once-daily oral medication for the treatment of motor symptoms of Parkinson’s disease. Tavapadon, which will be sold under the ...

The U.S. Food and Drug Administration (FDA) has approved a new, long-acting oral formulation for the treatment of Parkinson's disease. Developed by Amneal Pharmaceuticals, Crexont aims to offer ...